Tag Archives: entrectinib

October, 2018

September, 2018

May, 2017

February, 2015

  • 5 February

    Ignyta’s Lung Cancer Drug Receives Orphan Drug Status from the FDA

    Today, precision oncology biotechnology company Ignyta, Inc. announced that its lead candidate has been granted orphan drug designation from US health regulators. According to the company, the US Food and Drug Administration (FDA) granted Ignyta’s entrectinib orphan drug designation for the treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive and ALK-positive non-small …